RxDoctor Payments Data

Vlad Simianu, MD

Surgery · Seattle, WANPI 1689992273

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,000 of the $14,557 with a category attached, or 61.8%. 10 manufacturers reported payments, led by Intuitive Surgical at 57.2% of the total. Reporting peaked in 2021 at $5,182 and has fallen 77.3% since, to $1,177 in 2025.

$14,557in general payments, 2019–2025

Across 57 payments — averaging $255.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Davol Inc.$4K
  • Medtronic$1K
  • Asensus Surgical, Inc.$600
  • Stryker$303
  • KCI USA, Inc.$129
  • plus $454 from 4 others
$1,590in research payments, 2019–2025

Across 3 payments — averaging $529.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K

What the payments were for

  • Consulting fees$6004%
  • Speaking & faculty fees$9,00062%
  • Travel & lodging$1,3389%
  • Food & beverage$3,17622%
  • Education$4443%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,557 in reported general payments places this provider in the 85th percentile of 549 surgery providers in Washington.

See all surgery providers in Washington →

Medicare billing

Part B allowed, 2024
$120,078
Medicare patients
183
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl15$235
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl11$142
Metronidazole35$100
Neomycin Sulfate24$95
Ondansetron Hcl28$40
Metoclopramide Hcl34$38

Paid to pharmacies, not to this prescriber.

Other surgery in Seattle

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →